{"transactions":[{"id":696987,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy","published_at":"2026-08-04T20:10:32.000Z","date":"2026-07-31","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date."}],"balance_after":7500,"derivative":{"exercise_price":0.63,"exercise_date":"2027-07-31","expiration_date":"2036-07-31","underlying":"Voting Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-26-085189","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252524/000121390026085189/ownership.xml","form_type":"4"}},{"id":1092039,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-03T20:24:56.000Z","date":"2025-07-03","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders."}],"balance_after":7500,"derivative":{"exercise_price":6.77,"exercise_date":"2026-07-03","expiration_date":"2035-07-03","underlying":"Voting Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-25-061501","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252524/000121390025061501/ownership.xml","form_type":"4"}},{"id":1484616,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-10T22:15:36.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7500,"derivative":{"exercise_price":25.41,"exercise_date":"2025-06-06","expiration_date":"2034-06-06","underlying":"Voting Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-24-051398","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252524/000121390024051398/ownership.xml","form_type":"4"}},{"id":1563804,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:51:11.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14010,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":22.85,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":14010},"source":{"system":"sec-edgar","filing":"0000950170-24-035435","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035435/ownership.xml","form_type":"4"}},{"id":1563803,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:51:11.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":7.8,"expiration_date":"2033-01-24","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000950170-24-035435","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035435/ownership.xml","form_type":"4"}},{"id":1563802,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:51:11.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":67000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":2.94,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":67000},"source":{"system":"sec-edgar","filing":"0000950170-24-035435","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035435/ownership.xml","form_type":"4"}},{"id":1563801,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:51:11.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":32000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":5.78,"expiration_date":"2031-01-25","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0000950170-24-035435","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035435/ownership.xml","form_type":"4"}},{"id":1563800,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:51:11.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":49245,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":4.05,"expiration_date":"2030-05-14","underlying":"Common Stock","underlying_shares":49245},"source":{"system":"sec-edgar","filing":"0000950170-24-035435","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035435/ownership.xml","form_type":"4"}},{"id":1563799,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:51:11.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":27705,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":8.43,"expiration_date":"2029-01-28","underlying":"Common Stock","underlying_shares":27705},"source":{"system":"sec-edgar","filing":"0000950170-24-035435","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035435/ownership.xml","form_type":"4"}},{"id":1563798,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:51:11.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":11.69,"expiration_date":"2028-01-23","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0000950170-24-035435","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035435/ownership.xml","form_type":"4"}},{"id":1563797,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:51:11.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":7.47,"expiration_date":"2027-09-21","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0000950170-24-035435","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035435/ownership.xml","form_type":"4"}},{"id":1563796,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:51:11.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":5.5,"expiration_date":"2027-06-27","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000950170-24-035435","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035435/ownership.xml","form_type":"4"}},{"id":1563795,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:51:11.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":1.72,"expiration_date":"2026-06-27","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0000950170-24-035435","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035435/ownership.xml","form_type":"4"}},{"id":1563794,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:51:11.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":2.97,"expiration_date":"2025-06-23","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0000950170-24-035435","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035435/ownership.xml","form_type":"4"}},{"id":1563793,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:51:11.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":10,"expiration_date":"2025-01-06","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0000950170-24-035435","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035435/ownership.xml","form_type":"4"}},{"id":1563792,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-22T16:51:11.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":90000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024 (the \"Merger Agreement\"), by and among CymaBay Therapeutics, Inc. (\"CymaBay\"), Gilead Sciences, Inc., a Delaware corporation (\"Gilead\"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead (\"Purchaser\"), among other things, Purchaser merged with and into the Company (the \"Merger\").  Accordingly, each outstanding share of CymaBay common stock was converted into the right to receive a cash payment equal to $32.50, less applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-035435","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035435/ownership.xml","form_type":"4"}},{"id":1669897,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-01-26T18:10:46.000Z","date":"2024-01-24","kind":"grant","planned":false,"acquired":true,"shares":14010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the underlying shares monthly from January 1, 2024."}],"balance_after":14010,"derivative":{"exercise_price":22.85,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":14010},"source":{"system":"sec-edgar","filing":"0001062993-24-001416","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299324001416/form4.xml","form_type":"4"}},{"id":1771680,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-09-29T17:54:02.000Z","date":"2023-09-29","kind":"exercise","planned":true,"acquired":false,"shares":5249,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vested as to 1/3 of the underlying shares on January 6, 2014 and the remaining 2/3 of the underlying shares vested ratably on a monthly basis over the 48 months thereafter."}],"balance_after":0,"derivative":{"exercise_price":5,"expiration_date":"2024-01-05","underlying":"Common Stock","underlying_shares":5249},"source":{"system":"sec-edgar","filing":"0001062993-23-018622","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323018622/form4.xml","form_type":"4"}},{"id":1771679,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Appreciation Right","published_at":"2023-09-29T17:54:02.000Z","date":"2023-09-29","kind":"exercise","planned":true,"acquired":false,"shares":3372,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The incentive award (the \"Award\") was granted under the CymaBay 2013 Equity Incentive Plan and could be settled in cash or shares of CymaBay common stock, at the sole discretion of CymaBay. The shares subject to the Award vested in 48 equal monthly installments from the grant date."}],"balance_after":0,"derivative":{"exercise_price":5,"expiration_date":"2023-12-22","underlying":"Common Stock","underlying_shares":3372},"source":{"system":"sec-edgar","filing":"0001062993-23-018622","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323018622/form4.xml","form_type":"4"}},{"id":1771678,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-09-29T17:54:02.000Z","date":"2023-09-29","kind":"exercise","planned":true,"acquired":false,"shares":943,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vested as to 1/4 of the underlying shares on April 2, 2010 and the remaining 3/4 of the underlying shares vested ratably on a monthly basis over the 36 months thereafter."}],"balance_after":0,"derivative":{"exercise_price":5,"expiration_date":"2023-12-22","underlying":"Common Stock","underlying_shares":943},"source":{"system":"sec-edgar","filing":"0001062993-23-018622","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323018622/form4.xml","form_type":"4"}},{"id":1771677,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-09-29T17:54:02.000Z","date":"2023-09-29","kind":"exercise","planned":true,"acquired":false,"shares":6357,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vested as to 1/3 of the underlying shares on October 31, 2013 and the remaining 2/3 of the underlying shares vested ratably on a monthly basis over the 48 months thereafter."}],"balance_after":0,"derivative":{"exercise_price":5,"expiration_date":"2023-10-30","underlying":"Common Stock","underlying_shares":6357},"source":{"system":"sec-edgar","filing":"0001062993-23-018622","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323018622/form4.xml","form_type":"4"}},{"id":1771676,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-29T17:54:02.000Z","date":"2023-09-29","kind":"sale","planned":true,"acquired":false,"shares":15921,"price":15.6821,"value":249674.7141,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.54 to $15.89, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":90000,"source":{"system":"sec-edgar","filing":"0001062993-23-018622","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323018622/form4.xml","form_type":"4"}},{"id":1771675,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-29T17:54:02.000Z","date":"2023-09-29","kind":"exercise","planned":true,"acquired":true,"shares":15921,"price":5,"value":79605.0,"ownership":{"direct":true},"balance_after":105921,"source":{"system":"sec-edgar","filing":"0001062993-23-018622","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323018622/form4.xml","form_type":"4"}},{"id":1861948,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-08T22:43:52.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":47000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":47000,"derivative":{"exercise_price":1.6,"exercise_date":"2024-06-07","expiration_date":"2033-06-07","underlying":"Voting Common Stock","underlying_shares":47000},"source":{"system":"sec-edgar","filing":"0001213900-23-047571","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252524/000121390023047571/ownership.xml","form_type":"4"}},{"id":1919443,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2023-04-14T20:19:06.000Z","date":"2023-04-13","kind":"sale","planned":false,"acquired":false,"shares":9075,"price":1.4903,"value":13524.4725,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were sold by the Reporting Person solely in order to satisfy certain tax obligations in connection with the issuance of shares of the Issuer's common stock upon the vesting of restricted stock units."}],"balance_after":21175,"source":{"system":"sec-edgar","filing":"0001213900-23-029900","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252524/000121390023029900/ownership.xml","form_type":"4"}},{"id":2043974,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-01-27T16:34:49.000Z","date":"2023-01-25","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the underlying shares monthly from January 1, 2023."}],"balance_after":25000,"derivative":{"exercise_price":7.8,"expiration_date":"2033-01-24","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001062993-23-001499","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323001499/form4.xml","form_type":"4"}},{"id":2137558,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2022-10-14T00:05:32.000Z","date":"2022-10-12","kind":"grant","acquired":true,"shares":30250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are represented by restricted stock units (the \"RSU Award\"), 1/2 of which shall vest on each of April 12, 2023 and October 12, 2023, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":30250,"source":{"system":"sec-edgar","filing":"0001213900-22-063945","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252524/000121390022063945/ownership.xml","form_type":"4"}},{"id":2319885,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-03-23T22:04:54.000Z","date":"2022-03-21","kind":"grant","acquired":true,"shares":78045,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3rd of the shares subject to the option (the \"Option\") shall vest on December 7, 2022, and 1/3rd of the shares subject to the Option shall vest on each anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of the investment committee of Abingworth Bioventures VII, LP (\"ABV VII\") which approves investment and voting decisions by majority vote. Abingworth LLP provides advisory services to ABV VII and exercises investment and dispositive power over the securities held by ABV VII. Under an agreement between the Reporting Person and Abingworth LLP, the Reporting Person is deemed to hold the Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VII, and must exercise the Option solely upon the direction of Abingworth LLP."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"ABV VII may be deemed the indirect beneficial owner of the Option, and the Reporting Person may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VII. The Reporting Person disclaims beneficial ownership of the Option except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person, Abingworth LLP, ABV VII or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":78045,"derivative":{"exercise_price":3.54,"expiration_date":"2032-03-21","underlying":"Voting Common Stock","underlying_shares":78045},"source":{"system":"sec-edgar","filing":"0001213900-22-014569","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252524/000121390022014569/ownership.xml","form_type":"4"}},{"id":2424283,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-01-27T16:53:57.000Z","date":"2022-01-25","kind":"grant","acquired":true,"shares":67000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the underlying shares monthly from January 1, 2022."}],"balance_after":67000,"derivative":{"exercise_price":2.94,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":67000},"source":{"system":"sec-edgar","filing":"0001062993-22-001694","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299322001694/form4.xml","form_type":"4"}},{"id":2683271,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2021-06-03T23:44:09.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest monthly and fully vest on the earlier of June 2, 2022 or the day prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of Abingworth LLP (\"ALLP\"). ALLP provides advisory services to Abingworth Bioventures VI, LP (\"ABV VI\"). Under an agreement between the Reporting Person and ALLP, the Reporting Person is deemed to hold this Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VI, and must exercise the Option solely upon the direction of ALLP."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"ABV VI may be deemed the indirect beneficial owner of the Option, and the Reporting Person may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VI. The Reporting Person disclaims beneficial ownership of the Option except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person, ALLP, ABV VI or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":15000,"derivative":{"exercise_price":21.49,"expiration_date":"2031-06-01","underlying":"Common Stock, $0.001 par value per share","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000905718-21-000752","document":"vaxcyte_fm4jun22021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649094/000090571821000752/vaxcyte_fm4jun22021.xml","form_type":"4"}},{"id":2707517,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Preferred Stock","published_at":"2021-05-19T00:10:03.000Z","date":"2021-05-18","kind":"exercise","acquired":false,"shares":2187504,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by Abingworth Bioventures 8, LP (\"ABV 8\"). Abingworth Bioventures 8 GP LP (\"Abingworth GP\") serves as the general partner of ABV 8. Abingworth General Partner 8 LLP serves as the general partner of Abingworth GP. ABV 8 (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV 8. The Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a super majority vote, and no individual member has the sole control or voting power over the shares held by ABV 8."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the reporting person, ABV 8 or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Class A Common Stock","underlying_shares":2187504},"source":{"system":"sec-edgar","filing":"0001209191-21-033806","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1252524/000120919121033806/doc4.xml","form_type":"4"}},{"id":2707516,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-05-19T00:10:03.000Z","date":"2021-05-18","kind":"purchase","acquired":true,"shares":772727,"price":11,"value":8499997.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by Abingworth Bioventures 8, LP (\"ABV 8\"). Abingworth Bioventures 8 GP LP (\"Abingworth GP\") serves as the general partner of ABV 8. Abingworth General Partner 8 LLP serves as the general partner of Abingworth GP. ABV 8 (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV 8. The Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a super majority vote, and no individual member has the sole control or voting power over the shares held by ABV 8."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the reporting person, ABV 8 or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2960231,"source":{"system":"sec-edgar","filing":"0001209191-21-033806","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1252524/000120919121033806/doc4.xml","form_type":"4"}},{"id":2707515,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-05-19T00:10:03.000Z","date":"2021-05-18","kind":"exercise","acquired":true,"shares":2187504,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by Abingworth Bioventures 8, LP (\"ABV 8\"). Abingworth Bioventures 8 GP LP (\"Abingworth GP\") serves as the general partner of ABV 8. Abingworth General Partner 8 LLP serves as the general partner of Abingworth GP. ABV 8 (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV 8. The Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a super majority vote, and no individual member has the sole control or voting power over the shares held by ABV 8."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the reporting person, ABV 8 or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2187504,"source":{"system":"sec-edgar","filing":"0001209191-21-033806","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1252524/000120919121033806/doc4.xml","form_type":"4"}},{"id":2707514,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-05-19T00:10:03.000Z","date":"2021-05-17","kind":"purchase","acquired":true,"shares":17828,"price":12.0404,"value":214656.2512,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted-average price. The shares were purchased at prices ranging from $11.60 to $12.25. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":17828,"source":{"system":"sec-edgar","filing":"0001209191-21-033806","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252524/000120919121033806/doc4.xml","form_type":"4"}},{"id":2710054,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-18T00:34:38.000Z","date":"2021-05-13","kind":"grant","acquired":true,"shares":9925,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of May 13, 2022 or the 2022 annual meeting of stockholders."}],"balance_after":9925,"derivative":{"exercise_price":11,"expiration_date":"2031-05-12","underlying":"Class A Common Stock","underlying_shares":9925},"source":{"system":"sec-edgar","filing":"0001209191-21-033335","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1252524/000120919121033335/doc4.xml","form_type":"4"}},{"id":2888994,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-02-01T19:15:00.000Z","date":"2021-01-26","kind":"grant","acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the underlying shares monthly from January 1, 2021."}],"balance_after":32000,"derivative":{"exercise_price":5.78,"expiration_date":"2031-01-25","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001333277-21-000028","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000133327721000028/edgar.xml","form_type":"4"}},{"id":3102161,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-23T17:10:36.000Z","date":"2020-05-15","kind":"grant","acquired":true,"shares":49245,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in 12 equal monthly installments commencing on January 31, 2020, subject to the Reporting Person's continuous service to the Issuer as of each such date."}],"balance_after":49245,"derivative":{"exercise_price":4.05,"expiration_date":"2030-05-14","underlying":"Common Stock","underlying_shares":49245},"source":{"system":"sec-edgar","filing":"0001209191-20-038529","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000120919120038529/doc4.xml","form_type":"4"}},{"id":3105513,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series D Preferred Stock","published_at":"2020-06-18T20:09:02.000Z","date":"2020-06-16","kind":"exercise","acquired":false,"shares":298917,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of Series A, Series B, Series C and Series D Preferred Stock was convertible into shares of Common Stock, $0.001 par value per share (\"Common Stock\") on a one-for-one basis with no expiration date and automatically converted into Common Stock upon the closing of the initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of Series A, Series B, Series C and Series D Preferred Stock was convertible into shares of Common Stock, $0.001 par value per share (\"Common Stock\") on a one-for-one basis with no expiration date and automatically converted into Common Stock upon the closing of the initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of Series A, Series B, Series C and Series D Preferred Stock was convertible into shares of Common Stock, $0.001 par value per share (\"Common Stock\") on a one-for-one basis with no expiration date and automatically converted into Common Stock upon the closing of the initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock, $0.001 par value per share","underlying_shares":298917},"source":{"system":"sec-edgar","filing":"0000905718-20-000595","document":"vaxcyte_fm4jun1620.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1649094/000090571820000595/vaxcyte_fm4jun1620.xml","form_type":"4"}},{"id":3105512,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-06-18T20:09:02.000Z","date":"2020-06-16","kind":"exercise","acquired":false,"shares":454812,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of Series A, Series B, Series C and Series D Preferred Stock was convertible into shares of Common Stock, $0.001 par value per share (\"Common Stock\") on a one-for-one basis with no expiration date and automatically converted into Common Stock upon the closing of the initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of Series A, Series B, Series C and Series D Preferred Stock was convertible into shares of Common Stock, $0.001 par value per share (\"Common Stock\") on a one-for-one basis with no expiration date and automatically converted into Common Stock upon the closing of the initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of Series A, Series B, Series C and Series D Preferred Stock was convertible into shares of Common Stock, $0.001 par value per share (\"Common Stock\") on a one-for-one basis with no expiration date and automatically converted into Common Stock upon the closing of the initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock, $0.001 par value per share","underlying_shares":454812},"source":{"system":"sec-edgar","filing":"0000905718-20-000595","document":"vaxcyte_fm4jun1620.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1649094/000090571820000595/vaxcyte_fm4jun1620.xml","form_type":"4"}},{"id":3105511,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-06-18T20:09:02.000Z","date":"2020-06-16","kind":"exercise","acquired":false,"shares":1217074,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of Series A, Series B, Series C and Series D Preferred Stock was convertible into shares of Common Stock, $0.001 par value per share (\"Common Stock\") on a one-for-one basis with no expiration date and automatically converted into Common Stock upon the closing of the initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of Series A, Series B, Series C and Series D Preferred Stock was convertible into shares of Common Stock, $0.001 par value per share (\"Common Stock\") on a one-for-one basis with no expiration date and automatically converted into Common Stock upon the closing of the initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of Series A, Series B, Series C and Series D Preferred Stock was convertible into shares of Common Stock, $0.001 par value per share (\"Common Stock\") on a one-for-one basis with no expiration date and automatically converted into Common Stock upon the closing of the initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock, $0.001 par value per share","underlying_shares":1217074},"source":{"system":"sec-edgar","filing":"0000905718-20-000595","document":"vaxcyte_fm4jun1620.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1649094/000090571820000595/vaxcyte_fm4jun1620.xml","form_type":"4"}},{"id":3105510,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-06-18T20:09:02.000Z","date":"2020-06-16","kind":"exercise","acquired":false,"shares":2185415,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of Series A, Series B, Series C and Series D Preferred Stock was convertible into shares of Common Stock, $0.001 par value per share (\"Common Stock\") on a one-for-one basis with no expiration date and automatically converted into Common Stock upon the closing of the initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of Series A, Series B, Series C and Series D Preferred Stock was convertible into shares of Common Stock, $0.001 par value per share (\"Common Stock\") on a one-for-one basis with no expiration date and automatically converted into Common Stock upon the closing of the initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of Series A, Series B, Series C and Series D Preferred Stock was convertible into shares of Common Stock, $0.001 par value per share (\"Common Stock\") on a one-for-one basis with no expiration date and automatically converted into Common Stock upon the closing of the initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock, $0.001 par value per share","underlying_shares":2185415},"source":{"system":"sec-edgar","filing":"0000905718-20-000595","document":"vaxcyte_fm4jun1620.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1649094/000090571820000595/vaxcyte_fm4jun1620.xml","form_type":"4"}},{"id":3105509,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value per share","published_at":"2020-06-18T20:09:02.000Z","date":"2020-06-16","kind":"purchase","acquired":true,"shares":12500,"price":16,"value":200000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":4168718,"source":{"system":"sec-edgar","filing":"0000905718-20-000595","document":"vaxcyte_fm4jun1620.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1649094/000090571820000595/vaxcyte_fm4jun1620.xml","form_type":"4"}},{"id":3105508,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value per share","published_at":"2020-06-18T20:09:02.000Z","date":"2020-06-16","kind":"exercise","acquired":true,"shares":298917,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series A, Series B, Series C and Series D Preferred Stock was convertible into shares of Common Stock, $0.001 par value per share (\"Common Stock\") on a one-for-one basis with no expiration date and automatically converted into Common Stock upon the closing of the initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":4156218,"source":{"system":"sec-edgar","filing":"0000905718-20-000595","document":"vaxcyte_fm4jun1620.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1649094/000090571820000595/vaxcyte_fm4jun1620.xml","form_type":"4"}},{"id":3105507,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value per share","published_at":"2020-06-18T20:09:02.000Z","date":"2020-06-16","kind":"exercise","acquired":true,"shares":454812,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series A, Series B, Series C and Series D Preferred Stock was convertible into shares of Common Stock, $0.001 par value per share (\"Common Stock\") on a one-for-one basis with no expiration date and automatically converted into Common Stock upon the closing of the initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":3857301,"source":{"system":"sec-edgar","filing":"0000905718-20-000595","document":"vaxcyte_fm4jun1620.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1649094/000090571820000595/vaxcyte_fm4jun1620.xml","form_type":"4"}},{"id":3105506,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value per share","published_at":"2020-06-18T20:09:02.000Z","date":"2020-06-16","kind":"exercise","acquired":true,"shares":1217074,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series A, Series B, Series C and Series D Preferred Stock was convertible into shares of Common Stock, $0.001 par value per share (\"Common Stock\") on a one-for-one basis with no expiration date and automatically converted into Common Stock upon the closing of the initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":3402489,"source":{"system":"sec-edgar","filing":"0000905718-20-000595","document":"vaxcyte_fm4jun1620.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1649094/000090571820000595/vaxcyte_fm4jun1620.xml","form_type":"4"}},{"id":3105505,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value per share","published_at":"2020-06-18T20:09:02.000Z","date":"2020-06-16","kind":"exercise","acquired":true,"shares":2185415,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series A, Series B, Series C and Series D Preferred Stock was convertible into shares of Common Stock, $0.001 par value per share (\"Common Stock\") on a one-for-one basis with no expiration date and automatically converted into Common Stock upon the closing of the initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2185415,"source":{"system":"sec-edgar","filing":"0000905718-20-000595","document":"vaxcyte_fm4jun1620.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649094/000090571820000595/vaxcyte_fm4jun1620.xml","form_type":"4"}},{"id":3109012,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2020-06-16T22:27:45.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3 of the shares of Common Stock subject to the option vest on June 11, 2021, and 1/36 of the shares vest monthly thereafter."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of Abingworth LLP (\"ALLP\"). ALLP provides advisory services to Abingworth Bioventures VI, LP (\"ABV VI\"). Under an agreement between the Reporting Person and ALLP, the Reporting Person is deemed to hold this Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VI, and must exercise the Option solely upon the direction of ALLP."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"ABV VI may be deemed the indirect beneficial owner of the Option, and the Reporting Person may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VI. The Reporting Person disclaims beneficial ownership of the Option except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person, ALLP, ABV VI or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":40000,"derivative":{"exercise_price":16,"expiration_date":"2030-06-10","underlying":"Common Stock, $0.001 par value per share","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000905718-20-000586","document":"vaxcyte_fm4ajun1520.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649094/000090571820000586/vaxcyte_fm4ajun1520.xml","form_type":"4/A","original_submission_date":"2020-06-15"}},{"id":3110569,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2020-06-15T20:38:25.000Z","date":"2020-06-11","kind":"grant","acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3 of the shares of Common Stock subject to the option vest on June 11, 2021, and 1/36 of the shares vest monthly thereafter."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a member of Abingworth LLP (\"ALLP\"). ALLP provides advisory services to Abingworth Bioventures VI, LP (\"ABV VI\"). Under an agreement between the Reporting Person and ALLP, the Reporting Person is deemed to hold this Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VI, and must exercise the Option solely upon the direction of ALLP."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"ABV VI may be deemed the indirect beneficial owner of the Option, and the Reporting Person may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VI. The Reporting Person disclaims beneficial ownership of the Option except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person, ALLP, ABV VI or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":40000,"derivative":{"exercise_price":16,"expiration_date":"2030-06-10","underlying":"Common Stock, $0.001 par value per share","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000905718-20-000580","document":"vaxcyte_fm4jun1120.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649094/000090571820000580/vaxcyte_fm4jun1120.xml","form_type":"4"}},{"id":3681489,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2019-01-31T17:04:43.000Z","date":"2019-01-29","kind":"grant","acquired":true,"shares":27705,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option vests as to 1/12 of the underlying shares monthly from January 1, 2019."}],"balance_after":27705,"derivative":{"exercise_price":8.43,"expiration_date":"2029-01-28","underlying":"Common Stock","underlying_shares":27705},"source":{"system":"sec-edgar","filing":"0000905718-19-000089","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000090571819000089/ownership.xml","form_type":"4"}},{"id":3691849,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2019-01-18T21:32:23.000Z","date":"2018-12-18","kind":"sale","acquired":false,"shares":62925,"price":29.7047,"value":1869168.2475,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This amended Form 4 is being filed to correct the number of shares sold on December 18, 2018 and the number of shares beneficially owned following the transaction."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.18 to $30.62 per share, inclusive."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amended Form 4 is being filed to correct the number of shares sold on December 18, 2018 and the number of shares beneficially owned following the transaction."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1171268,"source":{"system":"sec-edgar","filing":"0000905718-19-000065","document":"crisprfm4a_dec192018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000090571819000065/crisprfm4a_dec192018.xml","form_type":"4/A","original_submission_date":"2018-12-19"}},{"id":3724663,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-12-19T21:22:59.000Z","date":"2018-12-18","kind":"sale","acquired":false,"shares":69925,"price":29.7047,"value":2077101.1475,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.18 to $30.62 per share, inclusive."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1164268,"source":{"system":"sec-edgar","filing":"0000905718-18-000981","document":"crisprfm4_dec172018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000090571818000981/crisprfm4_dec172018.xml","form_type":"4"}},{"id":3724662,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-12-19T21:22:59.000Z","date":"2018-12-17","kind":"sale","acquired":false,"shares":3009,"price":33.1662,"value":99797.0958,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.03 to $33.29 per share, inclusive."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1234193,"source":{"system":"sec-edgar","filing":"0000905718-18-000981","document":"crisprfm4_dec172018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000090571818000981/crisprfm4_dec172018.xml","form_type":"4"}},{"id":3725315,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-19T16:18:08.000Z","date":"2018-12-18","kind":"sale","acquired":false,"shares":53492,"price":7.4285,"value":397365.322,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.24 to $8.10 per share, inclusive."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Reporting Person undertakes to provide to Cymabay Therapeutics, Inc. (\"Issuer\") any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":131036,"source":{"system":"sec-edgar","filing":"0000905718-18-000979","document":"cymabaytherafm4_dec172018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000090571818000979/cymabaytherafm4_dec172018.xml","form_type":"4"}},{"id":3725314,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-19T16:18:08.000Z","date":"2018-12-17","kind":"sale","acquired":false,"shares":88889,"price":8.17,"value":726223.13,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.03 to $8.51 per share, inclusive."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Reporting Person undertakes to provide to Cymabay Therapeutics, Inc. (\"Issuer\") any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":184528,"source":{"system":"sec-edgar","filing":"0000905718-18-000979","document":"cymabaytherafm4_dec172018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000090571818000979/cymabaytherafm4_dec172018.xml","form_type":"4"}},{"id":3890864,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-18T20:21:23.000Z","date":"2018-06-15","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 15, 2018 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on May 30, 2018."}],"balance_after":15000,"derivative":{"exercise_price":59.31,"expiration_date":"2028-06-15","underlying":"Common Shares","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000905718-18-000569","document":"crisprfm4_jun152018.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000090571818000569/crisprfm4_jun152018.xml","form_type":"4"}},{"id":3898852,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to buy)","published_at":"2018-06-11T08:42:40.000Z","date":"2018-06-05","kind":"other","acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By The Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005"},"balance_after":0,"derivative":{"exercise_price":5.75,"exercise_date":"2013-09-30","expiration_date":"2018-09-30","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0000905718-18-000561","document":"cymabayfm4a_jun52018.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000090571818000561/cymabayfm4a_jun52018.xml","form_type":"4/A","original_submission_date":"2018-06-07"}},{"id":3898851,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-11T08:42:40.000Z","date":"2018-06-05","kind":"sale","acquired":false,"shares":920,"price":12.51,"value":11509.2,"ownership":{"direct":false,"nature":"By the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This amended Form 4 is being amended to correct the incorrect code used for acquisition of the warrant securities.  On June 5, 2018, Kurt von Emster (the \"Reporting Person\") on behalf of the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005, exercised a warrant to purchase 2,000 shares of CymaBay Therapeutics, Inc. (\"CBAY\") common stock for $5.75 per share. The Reporting Person paid the exercise price on a cashless basis, resulting in CBAY's withholding of 920 of the warrant shares to pay the exercise price and issuing to the Reporting Person the remaining 1,080 shares. CBAY also paid $9.47 to the Reporting Person in lieu of a fractional share."}],"balance_after":18316,"source":{"system":"sec-edgar","filing":"0000905718-18-000561","document":"cymabayfm4a_jun52018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000090571818000561/cymabayfm4a_jun52018.xml","form_type":"4/A","original_submission_date":"2018-06-07"}},{"id":3898850,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-11T08:42:40.000Z","date":"2018-06-05","kind":"other","acquired":true,"shares":2000,"price":5.75,"value":11500.0,"ownership":{"direct":false,"nature":"By the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005"},"balance_after":19236,"source":{"system":"sec-edgar","filing":"0000905718-18-000561","document":"cymabayfm4a_jun52018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000090571818000561/cymabayfm4a_jun52018.xml","form_type":"4/A","original_submission_date":"2018-06-07"}},{"id":3901723,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to buy)","published_at":"2018-06-07T20:36:39.000Z","date":"2018-06-05","kind":"other","acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By The Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005"},"balance_after":0,"derivative":{"exercise_price":5.75,"exercise_date":"2013-09-30","expiration_date":"2018-09-30","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0000905718-18-000554","document":"crispr-fm4_jun42018.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000090571818000554/crispr-fm4_jun42018.xml","form_type":"4"}},{"id":3901722,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-07T20:36:39.000Z","date":"2018-06-05","kind":"sale","acquired":false,"shares":920,"price":12.51,"value":11509.2,"ownership":{"direct":false,"nature":"By the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 5, 2018, Kurt von Emster (the \"Reporting Person\") on behalf of the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005, exercised a warrant to purchase 2,000 shares of CymaBay Therapeutics, Inc. (\"CBAY\") common stock for $5.75 per share. The Reporting Person paid the exercise price on a cashless basis, resulting in CBAY's withholding of 920 of the warrant shares to pay the exercise price and issuing to the Reporting Person the remaining 1,080 shares. CBAY also paid $9.47 to the Reporting Person in lieu of a fractional share."}],"balance_after":18316,"source":{"system":"sec-edgar","filing":"0000905718-18-000554","document":"crispr-fm4_jun42018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000090571818000554/crispr-fm4_jun42018.xml","form_type":"4"}},{"id":3901721,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-07T20:36:39.000Z","date":"2018-06-05","kind":"other","acquired":false,"shares":2000,"price":5.75,"value":11500.0,"ownership":{"direct":false,"nature":"By the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005"},"balance_after":19236,"source":{"system":"sec-edgar","filing":"0000905718-18-000554","document":"crispr-fm4_jun42018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000090571818000554/crispr-fm4_jun42018.xml","form_type":"4"}},{"id":3902143,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to buy)","published_at":"2018-06-07T19:30:14.000Z","date":"2018-06-05","kind":"other","acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By The Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 5, 2018, Kurt von Emster (\"Reporting Person\") on behalf of the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005, exercised a warrant to purchase 2,000 shares of CymaBay Therapeutics, Inc. (\"CBAY\") common stock for $5.75 per share. The Reporting Person paid the exercise price on a cashless basis, resulting in CBAY's withholding of 920 of the warrant shares to pay the exercise price and issuing to the Reporting Person the remaining 1,080 shares. CBAY also paid $9.47 to the Reporting Person in lieu of a fractional share."}],"balance_after":0,"derivative":{"exercise_price":5.75,"exercise_date":"2013-09-30","expiration_date":"2018-09-30","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0000905718-18-000559","document":"cymabaytherafm4_jun52018.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000090571818000559/cymabaytherafm4_jun52018.xml","form_type":"4"}},{"id":3902142,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-07T19:30:14.000Z","date":"2018-06-05","kind":"sale","acquired":false,"shares":920,"price":12.51,"value":11509.2,"ownership":{"direct":false,"nature":"By the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 5, 2018, Kurt von Emster (\"Reporting Person\") on behalf of the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005, exercised a warrant to purchase 2,000 shares of CymaBay Therapeutics, Inc. (\"CBAY\") common stock for $5.75 per share. The Reporting Person paid the exercise price on a cashless basis, resulting in CBAY's withholding of 920 of the warrant shares to pay the exercise price and issuing to the Reporting Person the remaining 1,080 shares. CBAY also paid $9.47 to the Reporting Person in lieu of a fractional share."}],"balance_after":18316,"source":{"system":"sec-edgar","filing":"0000905718-18-000559","document":"cymabaytherafm4_jun52018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000090571818000559/cymabaytherafm4_jun52018.xml","form_type":"4"}},{"id":3902141,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-07T19:30:14.000Z","date":"2018-06-05","kind":"other","acquired":false,"shares":2000,"price":5.75,"value":11500.0,"ownership":{"direct":false,"nature":"By the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005"},"balance_after":19236,"source":{"system":"sec-edgar","filing":"0000905718-18-000559","document":"cymabaytherafm4_jun52018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000090571818000559/cymabaytherafm4_jun52018.xml","form_type":"4"}},{"id":3933071,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-05-16T00:04:42.000Z","date":"2018-05-14","kind":"sale","acquired":false,"shares":8900,"price":52.1955,"value":464539.95,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Kurt von Emster's (the \"Reporting Person\") pecuniary interest in Abingworth Bioventures VI LP's (\"ABV VI\") May 11, 2018 and May 14, 2018 sales of common stock of CRISPR Therapeutics AG (\"Issuer\") reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of Reporting Person's pecuniary interest in Abingworth BioEquities Master Fund Limited's (\"ABE\") January 5, 2018 purchase of 65,934 shares of common stock of Issuer at a price of $22.75 per share. The Reporting Person has agreed to pay to Issuer the full amount of the Reporting Person's pecuniary interest in the profit realized in connection with the short-swing transactions, less transaction costs (rounded to the nearest dollar)."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.00 to $52.37 per share, inclusive."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1237202,"source":{"system":"sec-edgar","filing":"0000905718-18-000518","document":"crispr-fm4_may112018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000090571818000518/crispr-fm4_may112018.xml","form_type":"4"}},{"id":3933070,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-05-16T00:04:42.000Z","date":"2018-05-14","kind":"sale","acquired":false,"shares":20881,"price":52.9339,"value":1105312.7659,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Kurt von Emster's (the \"Reporting Person\") pecuniary interest in Abingworth Bioventures VI LP's (\"ABV VI\") May 11, 2018 and May 14, 2018 sales of common stock of CRISPR Therapeutics AG (\"Issuer\") reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of Reporting Person's pecuniary interest in Abingworth BioEquities Master Fund Limited's (\"ABE\") January 5, 2018 purchase of 65,934 shares of common stock of Issuer at a price of $22.75 per share. The Reporting Person has agreed to pay to Issuer the full amount of the Reporting Person's pecuniary interest in the profit realized in connection with the short-swing transactions, less transaction costs (rounded to the nearest dollar)."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.38 to $53.37 per share, inclusive."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1246102,"source":{"system":"sec-edgar","filing":"0000905718-18-000518","document":"crispr-fm4_may112018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000090571818000518/crispr-fm4_may112018.xml","form_type":"4"}},{"id":3933069,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-05-16T00:04:42.000Z","date":"2018-05-14","kind":"sale","acquired":false,"shares":53927,"price":53.8613,"value":2904578.3251,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Kurt von Emster's (the \"Reporting Person\") pecuniary interest in Abingworth Bioventures VI LP's (\"ABV VI\") May 11, 2018 and May 14, 2018 sales of common stock of CRISPR Therapeutics AG (\"Issuer\") reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of Reporting Person's pecuniary interest in Abingworth BioEquities Master Fund Limited's (\"ABE\") January 5, 2018 purchase of 65,934 shares of common stock of Issuer at a price of $22.75 per share. The Reporting Person has agreed to pay to Issuer the full amount of the Reporting Person's pecuniary interest in the profit realized in connection with the short-swing transactions, less transaction costs (rounded to the nearest dollar)."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.38 to $54.37 per share, inclusive."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1266983,"source":{"system":"sec-edgar","filing":"0000905718-18-000518","document":"crispr-fm4_may112018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000090571818000518/crispr-fm4_may112018.xml","form_type":"4"}},{"id":3933068,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-05-16T00:04:42.000Z","date":"2018-05-14","kind":"sale","acquired":false,"shares":126901,"price":54.9899,"value":6978273.2999,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Kurt von Emster's (the \"Reporting Person\") pecuniary interest in Abingworth Bioventures VI LP's (\"ABV VI\") May 11, 2018 and May 14, 2018 sales of common stock of CRISPR Therapeutics AG (\"Issuer\") reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of Reporting Person's pecuniary interest in Abingworth BioEquities Master Fund Limited's (\"ABE\") January 5, 2018 purchase of 65,934 shares of common stock of Issuer at a price of $22.75 per share. The Reporting Person has agreed to pay to Issuer the full amount of the Reporting Person's pecuniary interest in the profit realized in connection with the short-swing transactions, less transaction costs (rounded to the nearest dollar)."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.39 to $55.37 per share, inclusive."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1320910,"source":{"system":"sec-edgar","filing":"0000905718-18-000518","document":"crispr-fm4_may112018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000090571818000518/crispr-fm4_may112018.xml","form_type":"4"}},{"id":3933067,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-05-16T00:04:42.000Z","date":"2018-05-14","kind":"sale","acquired":false,"shares":73144,"price":55.7219,"value":4075722.6536,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Kurt von Emster's (the \"Reporting Person\") pecuniary interest in Abingworth Bioventures VI LP's (\"ABV VI\") May 11, 2018 and May 14, 2018 sales of common stock of CRISPR Therapeutics AG (\"Issuer\") reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of Reporting Person's pecuniary interest in Abingworth BioEquities Master Fund Limited's (\"ABE\") January 5, 2018 purchase of 65,934 shares of common stock of Issuer at a price of $22.75 per share. The Reporting Person has agreed to pay to Issuer the full amount of the Reporting Person's pecuniary interest in the profit realized in connection with the short-swing transactions, less transaction costs (rounded to the nearest dollar)."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.37 to $56.37 per share, inclusive."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1447811,"source":{"system":"sec-edgar","filing":"0000905718-18-000518","document":"crispr-fm4_may112018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000090571818000518/crispr-fm4_may112018.xml","form_type":"4"}},{"id":3933066,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-05-16T00:04:42.000Z","date":"2018-05-14","kind":"sale","acquired":false,"shares":116247,"price":56.8972,"value":6614128.8084,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Kurt von Emster's (the \"Reporting Person\") pecuniary interest in Abingworth Bioventures VI LP's (\"ABV VI\") May 11, 2018 and May 14, 2018 sales of common stock of CRISPR Therapeutics AG (\"Issuer\") reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of Reporting Person's pecuniary interest in Abingworth BioEquities Master Fund Limited's (\"ABE\") January 5, 2018 purchase of 65,934 shares of common stock of Issuer at a price of $22.75 per share. The Reporting Person has agreed to pay to Issuer the full amount of the Reporting Person's pecuniary interest in the profit realized in connection with the short-swing transactions, less transaction costs (rounded to the nearest dollar)."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.38 to $57.37 per share, inclusive."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1520955,"source":{"system":"sec-edgar","filing":"0000905718-18-000518","document":"crispr-fm4_may112018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000090571818000518/crispr-fm4_may112018.xml","form_type":"4"}},{"id":3933065,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-05-16T00:04:42.000Z","date":"2018-05-11","kind":"sale","acquired":false,"shares":8633,"price":51.7264,"value":446554.0112,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Kurt von Emster's (the \"Reporting Person\") pecuniary interest in Abingworth Bioventures VI LP's (\"ABV VI\") May 11, 2018 and May 14, 2018 sales of common stock of CRISPR Therapeutics AG (\"Issuer\") reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of Reporting Person's pecuniary interest in Abingworth BioEquities Master Fund Limited's (\"ABE\") January 5, 2018 purchase of 65,934 shares of common stock of Issuer at a price of $22.75 per share. The Reporting Person has agreed to pay to Issuer the full amount of the Reporting Person's pecuniary interest in the profit realized in connection with the short-swing transactions, less transaction costs (rounded to the nearest dollar)."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.45 to $51.94 per share, inclusive."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1637202,"source":{"system":"sec-edgar","filing":"0000905718-18-000518","document":"crispr-fm4_may112018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000090571818000518/crispr-fm4_may112018.xml","form_type":"4"}},{"id":3933064,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-05-16T00:04:42.000Z","date":"2018-05-11","kind":"sale","acquired":false,"shares":127890,"price":52.4561,"value":6708610.629,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Kurt von Emster's (the \"Reporting Person\") pecuniary interest in Abingworth Bioventures VI LP's (\"ABV VI\") May 11, 2018 and May 14, 2018 sales of common stock of CRISPR Therapeutics AG (\"Issuer\") reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of Reporting Person's pecuniary interest in Abingworth BioEquities Master Fund Limited's (\"ABE\") January 5, 2018 purchase of 65,934 shares of common stock of Issuer at a price of $22.75 per share. The Reporting Person has agreed to pay to Issuer the full amount of the Reporting Person's pecuniary interest in the profit realized in connection with the short-swing transactions, less transaction costs (rounded to the nearest dollar)."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.95 to $52.94 per share, inclusive."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1645835,"source":{"system":"sec-edgar","filing":"0000905718-18-000518","document":"crispr-fm4_may112018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000090571818000518/crispr-fm4_may112018.xml","form_type":"4"}},{"id":3933063,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-05-16T00:04:42.000Z","date":"2018-05-11","kind":"sale","acquired":false,"shares":113477,"price":53.3565,"value":6054735.5505,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Kurt von Emster's (the \"Reporting Person\") pecuniary interest in Abingworth Bioventures VI LP's (\"ABV VI\") May 11, 2018 and May 14, 2018 sales of common stock of CRISPR Therapeutics AG (\"Issuer\") reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of Reporting Person's pecuniary interest in Abingworth BioEquities Master Fund Limited's (\"ABE\") January 5, 2018 purchase of 65,934 shares of common stock of Issuer at a price of $22.75 per share. The Reporting Person has agreed to pay to Issuer the full amount of the Reporting Person's pecuniary interest in the profit realized in connection with the short-swing transactions, less transaction costs (rounded to the nearest dollar)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.95 to $53.94 per share, inclusive."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1773725,"source":{"system":"sec-edgar","filing":"0000905718-18-000518","document":"crispr-fm4_may112018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000090571818000518/crispr-fm4_may112018.xml","form_type":"4"}},{"id":4008689,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-07T16:19:50.000Z","date":"2018-03-05","kind":"sale","acquired":false,"shares":13353,"price":15.51,"value":207105.03,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP (\"ABV VI\") and Abingworth BioEquities Master Fund Limited (\"ABE\") on September 29, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.50 to $15.57 per share, inclusive. Kurt von Emster (the \"Reporting Person\") undertakes to provide to CymaBay Therapeutics, Inc. (\"CymaBay\"), any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by ABV VI and ABE, (ABE together with ABV VI, the \"Abingworth Funds\"). Abingworth LLP (\"Abingworth\") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":273417,"source":{"system":"sec-edgar","filing":"0000905718-18-000307","document":"cymabaytherafm4_mar52018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000090571818000307/cymabaytherafm4_mar52018.xml","form_type":"4"}},{"id":4048624,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-02-20T16:08:54.000Z","date":"2018-02-15","kind":"sale","acquired":false,"shares":68712,"price":14.49,"value":995636.88,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP (\"ABV VI\") and Abingworth BioEquities Master Fund Limited (\"ABE\") on September 29, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.53 to $14.87 per share, inclusive. Kurt von Emster (the \"Reporting Person\") undertakes to provide to CymaBay Therapeutics, Inc. (\"CymaBay\"), any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by ABV VI and ABE, (ABE together with ABV VI, the \"Abingworth Funds\"). Abingworth LLP (\"Abingworth\") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":286770,"source":{"system":"sec-edgar","filing":"0000905718-18-000263","document":"cymabaytherafm4_feb15018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000090571818000263/cymabaytherafm4_feb15018.xml","form_type":"4"}},{"id":4052485,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-02-16T14:44:39.000Z","date":"2018-02-14","kind":"sale","acquired":false,"shares":162979,"price":13.69,"value":2231182.51,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP (\"ABV VI\") and Abingworth BioEquities Master Fund Limited (\"ABE\") on September 29, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This amendment is being filed to correct the sale price of the securities. The sale price of the securities was misstated on Kurt von Emster's (the \"Reporting Person\") original Form 4 filed with the Securities and Exchange Commission on February 15, 2018. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.50 to $14.08 per share, inclusive. The Reporting Person undertakes to provide to CymaBay Therapeutics, Inc. (\"CymaBay\"), any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by ABV VI and ABE, (ABE together with ABV VI, the \"Abingworth Funds\"). Abingworth LLP (\"Abingworth\") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":355482,"source":{"system":"sec-edgar","filing":"0000905718-18-000260","document":"cymabaytherafm4am1_feb14018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000090571818000260/cymabaytherafm4am1_feb14018.xml","form_type":"4/A","original_submission_date":"2018-02-15"}},{"id":4055586,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-02-15T16:12:00.000Z","date":"2018-02-14","kind":"sale","acquired":false,"shares":162979,"price":16.69,"value":2720119.51,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP (\"ABV VI\") and Abingworth BioEquities Master Fund Limited (\"ABE\") on September 29, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.50 to $14.08 per share, inclusive. Reporting Person undertakes to provide to CymaBay any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by ABV VI and ABE, (ABE together with ABV VI, the \"Abingworth Funds\"). Abingworth LLP (\"Abingworth\") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":355482,"source":{"system":"sec-edgar","filing":"0000905718-18-000256","document":"cymabaytherafm4_feb13018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000090571818000256/cymabaytherafm4_feb13018.xml","form_type":"4"}},{"id":4055585,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-02-15T16:12:00.000Z","date":"2018-02-13","kind":"sale","acquired":false,"shares":55078,"price":13.51,"value":744103.78,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP (\"ABV VI\") and Abingworth BioEquities Master Fund Limited (\"ABE\") on September 29, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.50 to $13.75 per share, inclusive. Kurt von Emster (the \"Reporting Person\") undertakes to provide to CymaBay Therapeutics, Inc. (\"CymaBay\"), any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by ABV VI and ABE, (ABE together with ABV VI, the \"Abingworth Funds\"). Abingworth LLP (\"Abingworth\") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":518461,"source":{"system":"sec-edgar","filing":"0000905718-18-000256","document":"cymabaytherafm4_feb13018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000090571818000256/cymabaytherafm4_feb13018.xml","form_type":"4"}},{"id":4066470,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-02-12T16:09:09.000Z","date":"2017-07-19","kind":"purchase","acquired":true,"shares":153846,"price":6.5,"value":999999.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Kurt von Emster's (the \"Reporting Person\") pecuniary interest in Abingworth Bioventures VI, LP's (\"ABV VI\") July 19, 2017 purchase of 153,846 shares of common stock of CymaBay Therapeutics, Inc. (\"Issuer\") at a price of $6.50 per share reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of Reporting Person's pecuniary interest in the sales of common stock by ABV VI and Abingworth BioEquities Master Fund Limited (\"ABE\") made between September 28, 2017 and January 17, 2018. The Reporting Person has paid to Issuer $692.00, representing the full amount of the Reporting Person's pecuniary interest in the profit realized in connection with the short-swing transactions, less transaction costs (rounded to the nearest dollar)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"These shares were omitted from the Forms 4 filed by Reporting Person on October 2, 2017 and the twelve Form 4 filings made thereafter."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares purchased are held by ABV VI. Abingworth LLP (\"Abingworth\") is the investment manager of ABV VI and ABE (the \"Abingworth Funds\") and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1753846,"source":{"system":"sec-edgar","filing":"0000905718-18-000123","document":"cymabaytherafm4_july192017.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000090571818000123/cymabaytherafm4_july192017.xml","form_type":"4"}},{"id":4068853,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-02-09T16:17:35.000Z","date":"2018-02-07","kind":"sale","acquired":false,"shares":40763,"price":12.35,"value":503423.05,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP (\"ABV VI\") and Abingworth BioEquities Master Fund Limited (\"ABE\") on September 29, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.10 to $12.73 per share, inclusive. Kurt von Emster (the \"Reporting Person\") undertakes to provide to CymaBay Therapeutics, Inc. (\"CymaBay\"), any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by ABV VI and ABE, (ABE together with ABV VI, the \"Abingworth Funds\"). Abingworth LLP (\"Abingworth\") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":419693,"source":{"system":"sec-edgar","filing":"0000905718-18-000117","document":"cymabaytherafm4_feb72018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000090571818000117/cymabaytherafm4_feb72018.xml","form_type":"4"}},{"id":4072432,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-02-07T16:20:20.000Z","date":"2018-02-05","kind":"sale","acquired":false,"shares":18831,"price":12.14,"value":228608.34,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP (\"ABV VI\") and Abingworth BioEquities Master Fund Limited (\"ABE\") on September 29, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.10 to $12.30 per share, inclusive. Kurt von Emster (the \"Reporting Person\") undertakes to provide to CymaBay Therapeutics, Inc. (\"CymaBay\"), any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by ABV VI and ABE, (ABE together with ABV VI, the \"Abingworth Funds\"). Abingworth LLP (\"Abingworth\") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":460456,"source":{"system":"sec-edgar","filing":"0000905718-18-000115","document":"cymabaytherafm4_feb52018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000090571818000115/cymabaytherafm4_feb52018.xml","form_type":"4"}},{"id":4076774,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-02-05T16:07:55.000Z","date":"2018-02-02","kind":"sale","acquired":false,"shares":2000,"price":12.11,"value":24220.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP (\"ABV VI\") and Abingworth BioEquities Master Fund Limited (\"ABE\") on September 29, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.10 to $12.14 per share, inclusive. Reporting Person undertakes to provide to CymaBay any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by ABV VI and ABE, (ABE together with ABV VI, the \"Abingworth Funds\"). Abingworth LLP (\"Abingworth\") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":479287,"source":{"system":"sec-edgar","filing":"0000905718-18-000111","document":"cymabaytherafm4_feb12018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000090571818000111/cymabaytherafm4_feb12018.xml","form_type":"4"}},{"id":4076773,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-02-05T16:07:55.000Z","date":"2018-02-01","kind":"sale","acquired":false,"shares":88098,"price":12.15,"value":1070390.7,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP (\"ABV VI\") and Abingworth BioEquities Master Fund Limited (\"ABE\") on September 29, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.10 to $12.40 per share, inclusive. Kurt von Emster (the \"Reporting Person\") undertakes to provide to CymaBay Therapeutics, Inc. (\"CymaBay\"), any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by ABV VI and ABE, (ABE together with ABV VI, the \"Abingworth Funds\"). Abingworth LLP (\"Abingworth\") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":481287,"source":{"system":"sec-edgar","filing":"0000905718-18-000111","document":"cymabaytherafm4_feb12018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000090571818000111/cymabaytherafm4_feb12018.xml","form_type":"4"}},{"id":4082094,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-02-01T16:29:34.000Z","date":"2018-01-31","kind":"sale","acquired":false,"shares":12300,"price":12.23,"value":150429.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP (\"ABV VI\") and Abingworth BioEquities Master Fund Limited (\"ABE\") on September 29, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.10 to $12.49 per share, inclusive. Reporting Person undertakes to provide to CymaBay any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by ABV VI and ABE, (ABE together with ABV VI, the \"Abingworth Funds\"). Abingworth LLP (\"Abingworth\") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":569385,"source":{"system":"sec-edgar","filing":"0000905718-18-000096","document":"cymabaytherafm4_jan302018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000090571818000096/cymabaytherafm4_jan302018.xml","form_type":"4"}},{"id":4082093,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-02-01T16:29:34.000Z","date":"2018-01-30","kind":"sale","acquired":false,"shares":85339,"price":12.22,"value":1042842.58,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP (\"ABV VI\") and Abingworth BioEquities Master Fund Limited (\"ABE\") on September 29, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.10 to $12.55 per share, inclusive. Kurt von Emster (the \"Reporting Person\") undertakes to provide to CymaBay Therapeutics, Inc. (\"CymaBay\"), any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by ABV VI and ABE, (ABE together with ABV VI, the \"Abingworth Funds\"). Abingworth LLP (\"Abingworth\") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":581685,"source":{"system":"sec-edgar","filing":"0000905718-18-000096","document":"cymabaytherafm4_jan302018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000090571818000096/cymabaytherafm4_jan302018.xml","form_type":"4"}},{"id":4088457,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-01-26T20:40:30.000Z","date":"2018-01-24","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests as to 1/12 of the underlying shares monthly beginning February 1, 2018."}],"balance_after":16000,"derivative":{"exercise_price":11.69,"expiration_date":"2028-01-23","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0000905718-18-000074","document":"cymabaytherafm4_jan252018.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000090571818000074/cymabaytherafm4_jan252018.xml","form_type":"4"}},{"id":4088456,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-26T20:40:30.000Z","date":"2018-01-25","kind":"sale","acquired":false,"shares":39438,"price":12.18,"value":480354.84,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP (\"ABV VI\") and Abingworth BioEquities Master Fund Limited (\"ABE\") on September 29, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.10 to $12.32 per share, inclusive. Kurt von Emster (the \"Reporting Person\") undertakes to provide to CymaBay Therapeutics, Inc. (\"CymaBay\"), any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by ABV VI and ABE, (ABE together with ABV VI, the \"Abingworth Funds\"). Abingworth LLP (\"Abingworth\") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":667024,"source":{"system":"sec-edgar","filing":"0000905718-18-000074","document":"cymabaytherafm4_jan252018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000090571818000074/cymabaytherafm4_jan252018.xml","form_type":"4"}},{"id":4091263,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-24T16:02:19.000Z","date":"2018-01-22","kind":"sale","acquired":false,"shares":138253,"price":10.4,"value":1437831.2,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP (\"ABV VI\") and Abingworth BioEquities Master Fund Limited (\"ABE\") on September 29, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.20 to $10.59 per share, inclusive. Kurt von Emster (the \"Reporting Person\") undertakes to provide to CymaBay Therapeutics, Inc. (\"CymaBay\"), any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by ABV VI and ABE, (ABE together with ABV VI, the \"Abingworth Funds\"). Abingworth LLP (\"Abingworth\") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":706462,"source":{"system":"sec-edgar","filing":"0000905718-18-000070","document":"cymabaytherafm4_jan222018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000090571818000070/cymabaytherafm4_jan222018.xml","form_type":"4"}},{"id":4093774,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-22T17:26:53.000Z","date":"2018-01-19","kind":"sale","acquired":false,"shares":130584,"price":10.25,"value":1338486.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP (\"ABV VI\") and Abingworth BioEquities Master Fund Limited (\"ABE\") on September 29, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.20 to $10.46 per share, inclusive. Reporting Person undertakes to provide to CymaBay, any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by ABV VI and ABE, (ABE together with ABV VI, the \"Abingworth Funds\"). Abingworth LLP (\"Abingworth\") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":844715,"source":{"system":"sec-edgar","filing":"0000905718-18-000064","document":"cymabaytherafm4_jan182018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000090571818000064/cymabaytherafm4_jan182018.xml","form_type":"4"}},{"id":4093773,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-22T17:26:53.000Z","date":"2018-01-18","kind":"sale","acquired":false,"shares":13632,"price":10.21,"value":139182.72,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP (\"ABV VI\") and Abingworth BioEquities Master Fund Limited (\"ABE\") on September 29, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.20 to $10.24 per share, inclusive. Kurt von Emster (the \"Reporting Person\") undertakes to provide to CymaBay Therapeutics, Inc. (\"CymaBay\"), any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by ABV VI and ABE, (ABE together with ABV VI, the \"Abingworth Funds\"). Abingworth LLP (\"Abingworth\") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":975299,"source":{"system":"sec-edgar","filing":"0000905718-18-000064","document":"cymabaytherafm4_jan182018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000090571818000064/cymabaytherafm4_jan182018.xml","form_type":"4"}},{"id":4101390,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-01-12T02:00:33.000Z","date":"2018-01-05","kind":"purchase","acquired":true,"shares":65934,"price":22.75,"value":1499998.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by Abingworth Bioequities Master Fund Limited (\"ABE\"). Abingworth LLP is the investment manager of ABE and has been delegated with all investment and dispositive power over the securities held by ABE. The Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABE. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABE to employees of Abingworth LLP subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1887202,"source":{"system":"sec-edgar","filing":"0000905718-18-000054","document":"crisprabefm4_jan52018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000090571818000054/crisprabefm4_jan52018.xml","form_type":"4"}},{"id":4103131,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-01-09T21:39:07.000Z","date":"2018-01-05","kind":"sale","acquired":false,"shares":92337,"price":26.96,"value":2489405.52,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP (\"Abingworth\") on May 15, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.50 to $28.35 per share, inclusive. Kurt von Emster (the \"Reporting Person\") undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by Abingworth. Abingworth Bioventures VI GP LP (\"Abingworth GP\") serves as the general partner of Abingworth. Abingworth General Partner VI LLP, serves as the general partner of Abingworth GP. Abingworth (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VI LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by Abingworth. The Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":1821268,"source":{"system":"sec-edgar","filing":"0000905718-18-000047","document":"crisprfm4_jan52018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000090571818000047/crisprfm4_jan52018.xml","form_type":"4"}},{"id":4103411,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-09T16:34:53.000Z","date":"2018-01-05","kind":"sale","acquired":false,"shares":4300,"price":10.21,"value":43903.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP (\"ABV VI\") and Abingworth BioEquities Master Fund Limited (\"ABE\") on September 29, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.20 to $10.24 per share, inclusive. Kurt von Emster (the \"Reporting Person\") undertakes to provide to CymaBay Therapeutics, Inc. (\"CymaBay\"), any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by ABV VI and ABE, (ABE together with ABV VI, the \"Abingworth Funds\"). Abingworth LLP (\"Abingworth\") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":988931,"source":{"system":"sec-edgar","filing":"0000905718-18-000045","document":"cymabaytherafm4_jan52018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000090571818000045/cymabaytherafm4_jan52018.xml","form_type":"4"}},{"id":4107632,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2018-01-04T22:29:30.000Z","date":"2018-01-02","kind":"sale","acquired":false,"shares":37754,"price":26.7554,"value":1010123.3716,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP (\"Abingworth\") on May 15, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.50 to $27.36 per share, inclusive. Kurt von Emster (the \"Reporting Person\") undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by Abingworth. Abingworth Bioventures VI GP LP (\"Abingworth GP\") serves as the general partner of Abingworth. Abingworth General Partner VI LLP, serves as the general partner of Abingworth GP. Abingworth (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VI LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by Abingworth. The Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":1913605,"source":{"system":"sec-edgar","filing":"0000905718-18-000020","document":"crisprfm4_jan22018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000090571818000020/crisprfm4_jan22018.xml","form_type":"4"}},{"id":4121160,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-12-27T16:08:05.000Z","date":"2017-12-22","kind":"sale","acquired":false,"shares":173192,"price":9.4075,"value":1629303.74,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP (\"ABV VI\") and Abingworth BioEquities Master Fund Limited (\"ABE\") on September 29, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.25 to $9.7760 per share, inclusive. Kurt von Emster (the \"Reporting Person\") undertakes to provide to CymaBay Therapeutics, Inc. (\"CymaBay\"), any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by ABV VI and ABE, (ABE together with ABV VI, the \"Abingworth Funds\"). Abingworth LLP (\"Abingworth\") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":993231,"source":{"system":"sec-edgar","filing":"0000905718-17-001042","document":"cymabaytherafm4_dec222017.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000090571817001042/cymabaytherafm4_dec222017.xml","form_type":"4"}},{"id":4164015,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-11-14T17:48:05.000Z","date":"2017-11-10","kind":"sale","acquired":false,"shares":50048,"price":9.2587,"value":463379.4176,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP (\"ABV VI\") and Abingworth BioEquities Master Fund Limited (\"ABE\") on September 29, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.25 to $9.30 per share, inclusive. Kurt von Emster (the \"Reporting Person\") undertakes to provide to CymaBay Therapeutics, Inc. (\"CymaBay\"), any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by ABV VI and ABE, (ABE together with ABV VI, the \"Abingworth Funds\"). Abingworth LLP (\"Abingworth\") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":1166423,"source":{"system":"sec-edgar","filing":"0000905718-17-000974","document":"cymabaytherafm4_111017.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000090571817000974/cymabaytherafm4_111017.xml","form_type":"4"}},{"id":4173185,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-11-03T16:52:38.000Z","date":"2017-11-01","kind":"sale","acquired":false,"shares":4320,"price":9.2545,"value":39979.44,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP (\"ABV VI\") and Abingworth BioEquities Master Fund Limited (\"ABE\") on September 29, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.25 to $9.32 per share, inclusive. Kurt von Emster (the \"Reporting Person\") undertakes to provide to CymaBay Therapeutics, Inc. (\"CymaBay\"), any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by ABV VI and ABE, (ABE together with ABV VI, the \"Abingworth Funds\"). Abingworth LLP (\"Abingworth\") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":1216471,"source":{"system":"sec-edgar","filing":"0000905718-17-000942","document":"cymabaytherafm4_nov12017.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000090571817000942/cymabaytherafm4_nov12017.xml","form_type":"4"}},{"id":4176595,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-11-01T16:39:22.000Z","date":"2017-10-31","kind":"sale","acquired":false,"shares":52573,"price":9.27,"value":487351.71,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP (\"ABV VI\") and Abingworth BioEquities Master Fund Limited (\"ABE\") on September 29, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.25 to $9.37 per share, inclusive. Reporting Person undertakes to provide to CymaBay, any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by ABV VI and ABE, (ABE together with ABV VI the \"Abingworth Funds\"). Abingworth LLP (\"Abingworth\") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":1220791,"source":{"system":"sec-edgar","filing":"0000905718-17-000938","document":"cymabaytherafm4_oct302017.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000090571817000938/cymabaytherafm4_oct302017.xml","form_type":"4"}},{"id":4176594,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-11-01T16:39:22.000Z","date":"2017-10-30","kind":"sale","acquired":false,"shares":6636,"price":9.26,"value":61449.36,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP (\"ABV VI\") and Abingworth BioEquities Master Fund Limited (\"ABE\") on September 29, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.25 to $9.35 per share, inclusive. Kurt von Emster (the \"Reporting Person\") undertakes to provide to CymaBay Therapeutics, Inc. (\"CymaBay\"), any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by ABV VI and ABE, (ABE together with ABV VI the \"Abingworth Funds\"). Abingworth LLP (\"Abingworth\") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":1273364,"source":{"system":"sec-edgar","filing":"0000905718-17-000938","document":"cymabaytherafm4_oct302017.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000090571817000938/cymabaytherafm4_oct302017.xml","form_type":"4"}},{"id":4192440,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26596,"kind":"person","name":"EMSTER KURT VON","position":1,"cik":"0001252524","reported_name":"EMSTER KURT VON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-10-04T16:02:40.000Z","date":"2017-10-03","kind":"sale","acquired":false,"shares":70940,"price":7.81,"value":554041.4,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.61 to $8.02 per share, inclusive. Reporting Person undertakes to provide to CymaBay, any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by Abingworth Bioventures VI, LP (\"ABV VI\") and Abingworth Bioequities Master Fund Limited (\"ABE\" and collectively with ABV VI the \"Abingworth Funds\"). Abingworth LLP (\"Abingworth\") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":1280000,"source":{"system":"sec-edgar","filing":"0000905718-17-000867","document":"cymabaytherafm4_oct22017.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000090571817000867/cymabaytherafm4_oct22017.xml","form_type":"4"}}],"next_cursor":"2017-10-04T16:02:40.000000Z,4192440"}